Baird analyst Jack Allen downgraded Bluebird Bio (BLUE) to Neutral from Outperform with a price target of $5, down from $54, after the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback